Market Snapshot

S&P Futures
4,196.00
Dow Futures
34,453.00
NASDAQ Futures
13,607.50

0.94$-0.09 -8.74%
At close    04:00 PM   
From: To:

Stock Snapshot

1.03
Prev. Close
1.03
Open
72.09M
Market Cap
5.08M
Number of Shares
0.9038
Day Low
1.0300
Day High
0.94
-
P/E Ratio
56.81M
Free Float in %
-0.55
EPS 2021
0.54
Book Value per Share
0.41
Cash Flow per Share
Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Inc. (RGLS) stock rallied over -8.74% intraday to trade at $0.94 per share on NASDAQ. The stock opened with a fall of 0.00% at $1.03 and touched an intraday high of $1.0300, 0.00% against the last close of $1.03. The stock went to a low of $0.9038 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-05-06$1.03$0.94$0.94$1.03$0.902,309,403
2021-05-05$1.06$1.03$1.03$1.08$1.021,502,700
2021-05-04$1.08$1.09$1.09$1.13$1.041,708,400
2021-05-03$1.36$1.12$1.12$1.39$1.037,615,000
2021-04-30$1.44$1.39$1.39$1.46$1.38536,800
2021-04-29$1.52$1.47$1.47$1.53$1.45442,500
2021-04-28$1.47$1.53$1.53$1.55$1.41592,700
2021-04-27$1.46$1.47$1.47$1.49$1.40854,000
2021-04-26$1.40$1.45$1.45$1.47$1.37651,000
2021-04-23$1.30$1.43$1.43$1.43$1.30991,100
2021-04-22$1.21$1.30$1.30$1.31$1.19720,200
Regulus Therapeutics Inc.
10628 Science Center Drive
Suite 225
San Diego, CA 92121
United States

http://www.regulusrx.com
858 202 6300
Employees
24
Sector
Healthcare
Sales or Revenue
10.00M
Industry
Biotechnology
5Y Sales Change
-13.60
Fiscal Year Ends
2020-12-30
Mr. Joseph P. Hagan M.B.A.
Pres, CEO & Director
Ms. Crispina Calsada
Chief Financial Officer
Mr. Christopher Ray Aker J.D.
Sr. VP. Gen. Counsel & Corp. Sec.
Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.